{"id":"NCT05064397","sponsor":"H. Lundbeck A/S","briefTitle":"A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)","officialTitle":"Interventional, Open-label, Fixed-dose Multiple Administration Study to Evaluate Long-term Treatment With Eptinezumab in Patients With Chronic Cluster Headache","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-09-17","primaryCompletion":"2023-06-29","completion":"2023-06-29","firstPosted":"2021-10-01","resultsPosted":"2024-08-06","lastUpdate":"2024-08-06"},"enrollment":131,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Cluster Headache"],"interventions":[{"type":"DRUG","name":"Eptinezumab","otherNames":["Vyepti"]}],"arms":[{"label":"Eptinezumab","type":"EXPERIMENTAL"}],"summary":"The main goal of this trial is to inform about long-term safety and tolerability of eptinezumab in participants with chronic cluster headache.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (AEs)","timeFrame":"From the day of first dose of study drug (Baseline [Week 0]) up to Week 56","effectByArm":[{"arm":"Eptinezumab","deltaMin":106,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":31,"countries":["United States","Denmark","Finland","France","Germany","Italy","Netherlands","Spain","United Kingdom"]},"refs":{"pmids":["40252664"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":131},"commonTop":["COVID-19","Nasopharyngitis","Fatigue","Influenza","Back pain"]}}